Gregory J. Lynch

Greg is a distinguished senior attorney in the firm’s Corporate practice group who has more than 25 years of experience in Mergers and Acquisitions and Corporate Financing transactions. He has assisted clients with numerous mergers and acquisitions, initial public offerings, venture capital, and private equity transactions, across a variety of industries.

As co-founder of the firm’s Venture Best emerging technology practice, Greg works with both early-stage companies and investors and as a result has the ability to efficiently arrive at solutions that serve his clients’ interests. Greg regularly serves as outside general counsel for clients ranging from start-up companies with high growth potential to multi-billion dollar companies.

Greg also has served on or represented dozens of Board of Directors for public companies, private companies, and non-profit organizations, and is regularly sought for his strategic advice. He works hard to understand his clients’ strategic goals, and tailors his legal advice in light of those business objectives.

Perhaps because of his differentiated combination of strategic business and legal experience, Greg regularly receives recognition from clients and peers, including being named “Lawyer of the Year” for Corporate practice (Madison market) by The Best Lawyers in America® in 2012, 2016, 2018 and 2020.

Solutions in action

Mergers & Acquisitions

• Represented medical device seller in a $150M sale to a financial buyer
• Represented family-owned seller of a manufacturing business in a $700M sale to a strategic buyer
• Represented strategic buyer in a $800M acquisition of a Tier 1 automotive supplier
• Represented strategic buyer in a $350M acquisition of a Tier 1 automotive supplier
• Represented information technology company in a $235M sale to a strategic buyer
• Represented family-owned manufacturing company in a $140M sale to a strategic buyer
• Represented diversified manufacturing company in a $75M acquisition of a manufacturing company
• Represented consumer goods company in a $50M sale to a strategic buyer
• Represented financial buyer in a $25M acquisition of an animal feed company

Public and Rule 144A Offerings

• Represented medical device company in a $220M public offering of common stock
• Represented automotive company in a $180M public offering of common stock
• Represented automotive company in a $100M public offering of common stock
• Represented manufacturing in a $50M public offering of common stock
• Represented underwriter in a $1.6B offering of debt securities
• Represented underwriter in $60M public offering of common stock
• Served on Board of Directors of a biotechnology company in a $50M initial public offering
• Represented biotechnology company in a $20M public offering of common stock and warrants
• Represented biotechnology company in a $15M public offering of common stock and warrants
• Represented underwriter in a $150M Rule 144A offering of debt securities
• Represented underwriter in a $100M Rule 144A offering of debt securities

Venture Capital and Private Equity Transactions

• Represented medical device company in a $20M Series A financing
• Represented biotechnology company in a $25M Series B financing
• Represented pharmaceutical company in a $27M Series C financing
• Represented medical information technology in a $20M Series B financing
• Represented lead investor in a $30M Series C financing
• Represented medical device company in a $40M Series D financing
• Represented biotechnology company in a $20M Series A financing

Strategic Licensing Agreements

• Represented licensor in a $120M (plus royalties) license to a global pharmaceutical company. Payments include up-front license and milestone payments
• Represented investor in a portfolio company for $300M license (plus royalties) to strategic partner. Payments include up-front license and milestone payments.
• Represented licensor in dozens of licenses to strategic partners for different fields of use for aggregate potential consideration in excess of $50M (plus royalties).